Evidence map›Paper›PMID 26090850›Full record

ArticlePloS one2015

Exonic Re-Sequencing of the Chromosome 2q24.3 Parkinson's Disease Locus.

Catherine Labbé, Kotaro Ogaki, Oswaldo Lorenzo-Betancor, Minerva M Carrasquillo, Michael G Heckman, Allan McCarthy, Alexandra I Soto-Ortolaza, Ronald L Walton, Timothy Lynch, Joanna Siuda and 8 more

Open access · goldAbstract read
In one paragraph

Article in PloS one, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact, top 98% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 1 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 8 institutions in 3 countries.

Catherine LabbéDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Kotaro OgakiDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Oswaldo Lorenzo-BetancorDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Minerva M CarrasquilloDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Michael G HeckmanSection of Biostatistics, Mayo Clinic, Jacksonville, Florida, United States of America.
Allan McCarthyDublin Neurological Institute at the Mater Misericordiae University Hospital, Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland.
Alexandra I Soto-OrtolazaDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Ronald L WaltonDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Timothy LynchDublin Neurological Institute at the Mater Misericordiae University Hospital, Conway Institute of Biomolecular & Biomedical Research, University College Dublin, Dublin, Ireland.
Joanna SiudaDepartment of Neurology, Medical University of Silesia, Katowice, Poland.
Grzegorz OpalaDepartment of Neurology, Medical University of Silesia, Katowice, Poland.
Anna Krygowska-WajsDepartment of Neurology, Jagiellonian University, Krakow, Poland.
Maria BarcikowskaDepartment of Neurodegenerative Disorders, Medical Research Centre, Polish Academy of Sciences, Warsaw, Poland.
Krzysztof CzyzewskiDepartment of Neurology, Central Hospital of the Ministry of Interior and Administration, Warsaw, Poland.
Dennis W DicksonDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, United States of America; Department of Pathology, Mayo Clinic, Jacksonville, Florida, United States of America.
Ryan J UittiDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, United States of America.
Zbigniew K WszolekDepartment of Neurology, Mayo Clinic, Jacksonville, Florida, United States of America.
Owen A RossDepartment of Neuroscience, Mayo Clinic, Jacksonville, Florida, United States of America.
Mayo Clinic in Florida · USMedical University of Silesia · PLWinnMed · USJagiellonian University · PLMater Misericordiae University Hospital · IEMinistry of Interior and Administration · PLPolish Academy of Sciences · PLUniversity College Dublin · IE

Funding

Neuropathology CoreP50NS072187 · NINDS · MAYO CLINIC JACKSONVILLE · PI DICKSON, DENNIS WILLIAM · 2010 to 2017
$8.7M
Understanding the role of MAPT in Parkinsonian disordersR01NS078086 · NINDS · MAYO CLINIC JACKSONVILLE · PI ROSS, OWEN A · 2012 to 2016
$1.7M
NINDS NIH HHS P50 NS072187NINDS NIH HHS R01 NS078086
6 · The paper itself

Abstract

Genome-wide association studies (GWAS) in Parkinson's disease (PD) have identified over 20 genomic regions associated with disease risk. Many of these loci include several candidate genes making it difficult to pinpoint the causal gene. The locus on chromosome 2q24.3 encompasses three genes: B3GALT1, STK39, and CERS6. In order to identify if the causal variants are simple missense changes, we sequenced all 31 exons of these three genes in 187 patients with PD. We identified 13 exonic variants including four non-synonymous and three insertion/deletion variants (indels). These non-synonymous variants and rs2102808, the GWAS tag SNP, were genotyped in three independent series consisting of a total of 1976 patients and 1596 controls. Our results show that the seven identified 2q24.3 coding variants are not independently responsible for the GWAS association signal at the locus; however, there is a haplotype, which contains both rs2102808 and a STK39 exon 1 6bp indel variant, that is significantly associated with PD risk (Odds Ratio [OR] = 1.35, 95% CI: 1.11-1.64, P = 0.003). This haplotype is more associated than each of the two variants independently (OR = 1.23, P = 0.005 and 1.10, P = 0.10, respectively). Our findings suggest that the risk variant is likely located in a non-coding region. Additional sequencing of the locus including promoter and regulatory regions will be needed to pinpoint the association at this locus that leads to an increased risk to PD.

Indexed as

Chromosomes, Human, Pair 2ExonsGenetic Association StudiesQuantitative Trait LociAgedAged, 80 and overAllelesCase-Control StudiesFemaleGenome-Wide Association StudyHaplotypesHigh-Throughput Nucleotide SequencingHumansINDEL MutationMaleMiddle AgedProtein Serine-Threonine KinasesSTK39 protein, human

Identifiers

PMID26090850
PMCPMC4474914
OpenAlexW1560359030

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.